EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies.

Evolut Low Risk

This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress and published in the New England Journal of Medicine (NEJM). At the time, a Bayesian analysis had been performed to estimate two-year outcomes when 850 of the 1414 patients included had reached only one year of follow-up.

All patients have now reached two years of follow-up and the plan is to extend the follow-up to 10 years.

After two years, the primary endpoint (all-cause mortality and disabling stroke) was observed in 4.3% of those who underwent TAVR vs. 6.3% of those who underwent surgery. This difference was not statistically significant, which confirms non-inferiority—albeit non-superiority.

When considering the endpoints separately, we see that all-cause mortality was 3.5% vs. 4.4% (p = 0.366), and disabling stroke was 1.5% vs. 2.7% (= 0.11).

Differences were found in the need of permanent pacemaker, regarding which surgery was better (21.1% for TAVR vs. 7.9% for surgery).


Read also: EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development.


Over these two years, better implantation techniques were developed using Evolut, such as overlapping the valves, which could reduce the difference. Something similar happens with paravalvular leak, regarding which surgery was superior (mild leaks: 26.6% for TAVR vs. only 2.6% for surgery; p < 0.001). However, the same technique refinement that improved the need for pacemaker also had an impact on leaks.

In terms of valve hemodynamics, Evolut had lower gradients and larger valvular areas than surgical ones.

Original Title: Complete 2-year follow-up from the Evolut low risk trial.

Reference: Presentado por Forrest J. en el EuroPCR 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...